← Wipeout · Sage hub

Sage — Endocrinology and Metabolism

Coach Sage

Topics in this chapter

  • Diabetes — Sequestration; water, water everywhere
  • Obesity — Engine vs GLP-1 dashboard
  • Thyroid — Labs as dashboard of metabolic persistence
  • Signals — Messages + energy dashboards as compensation
  • Serotonin — Bioenergetic flux manager
  • Calcium — Bone as the dynamic reservoir, not a static scaffold
  • Adenosine — Adenosine as the Primary Energy-Stress Signal

Conventional endocrinology: powerful axis tools, incomplete upstream story

Textbook and clinic paradigms emphasize hypothalamic–pituitary–target axes, receptor–ligand kinetics, feedback loops, polymorphisms, and autoantibodies. Insulin resistance is attributed to post-receptor defects; leptin resistance to hypothalamic inflammation or receptor variants; hypothyroidism to glandular failure or Hashimoto’s; HPA issues to “adrenal dysregulation.” Treatments target the signal or receptor directly: insulin or sensitizers, thyroid replacement, GLP-1 receptor agonists, anti-androgens, HRT, blockers. These yield symptomatic improvement and are lifesaving in acute deficiency or excess — and they have not stemmed the epidemics of metabolic disease, obesity, T2DM, PCOS, thyroid disorders, or sarcopenia. They often manage downstream manifestations while cellular engines remain compromised, sometimes creating dependency or new imbalances (for example, exogenous insulin in a setting of mitochondrial dysfunction may drive further oxidative stress or weight gain).

Good Doctor, in brief: quality of diagnosis is whether the name points at the layer where action shrinks the residual. “Optimize the panel” and “restore the engine that forced the panel to scream” can both be true; only one tells you what else to do when labs look “fine” and the person does not. This page is not a peptide, HRT, or GLP-1 how-to guide; those topics stay at the level of the hypothesis paragraphs here and on the Diabetes and Obesity pages.

Endocrine axes as compensation for cellular energy insufficiency

Insulin. In mitochondrial inefficiency — hyperglycemia-driven ROS, lipid overload peroxidizing cardiolipin, cofactor shortfalls, circadian disruption of biogenesis — peripheral cells cannot oxidize fuels cleanly. On this hypothesis, insulin resistance emerges not primarily as a defect but as a higher-level tolerance and redirection mechanism: hyperinsulinemia attempts mass-action uptake; resistance in non-priority tissues redirects glucose toward obligatory users and supports alternative fuel strategies when adapted. Post-receptor signaling itself consumes ATP and requires redox balance; energy-stressed cells desensitize it to limit futile cycling. In cell and mouse studies, insulin resistance acted as a defense against mitochondrial oxidant stress; whether reduced mitochondrial capacity causes insulin resistance is still debated. Conventional focus on IRS-1 or GLUT4 misses that those steps presuppose mitochondrial capacity to use delivered glucose. Fuel shift and biogenesis may improve sensitivity, sometimes quickly, as shown with short-term energy restriction; ketogenic or carnivore transitions before weight loss are less studied (hypothesis, not a Surfer diet order). Detail: Sage — Diabetes · Sage — Obesity.

Leptin. In energy surplus with poor utilization, leptin resistance in arcuate circuits recalibrates appetite and expenditure — readable as the brain interpreting adipose signals against cellular inability to burn stored energy efficiently, not only as primary hypothalamic failure (whether leptin resistance is cause or effect of obesity is debated). Ultra-processed carbs and seed oils worsen both adipose expansion and mitochondrial substrate damage.

Thyroid. Dedicated depth: Sage — Thyroid. Non-thyroidal illness (euthyroid sick) — low T3, normal/high rT3 — is often interpreted as adaptive downregulation of expenditure when engines are compromised. Chronic low-grade versions appear in metabolic disease and aging as “subclinical hypothyroidism” or functional hypothyroid symptoms despite TSH that looks acceptable on a narrow dashboard. Exogenous T4/T3 can bypass sensing without restoring capacity; symptoms may recur if mitochondrial substrate remains poor. Improving mito function via lifestyle may, on this hypothesis (untested), normalize thyroid economy in functional cases without replacement — and replacement remains appropriate when true glandular failure or myxedema risk is present. Labs are often dashboard readings of inadequate metabolic persistence, not the whole ontology of the disease.

Cortisol / HPA. Chronic activation mobilizes glucose, FFAs, and amino acids when immediate ATP falters. Short-term adaptive; long-term catabolic, insulin-antagonizing, and sleep-disrupting. “Adrenal fatigue” as a primary gland failure story often misses persistent level 0–1 demand that never closes. Cortisol is the daily-wavelength dashboard; adenosine is the high-frequency one (Sage — Signals).

Sex steroids / PCOS / menopause–andropause. Anabolism, neuroprotection, and vascular health require energy; resistance or altered sensitivity emerges in energy-poor states. In PCOS, IR coexists with ovarian hyperandrogenism; theca mito stress or systemic fuel misallocation may drive compensatory androgen output. Timing and symptoms of menopause/andropause partly reflect cumulative mito decline reducing gonadal reserve and tissue responsiveness. Engine restoration may ameliorate symptoms and sometimes balance without treating HRT as first and only lever — while HRT remains a legitimate clinical tool when indicated. No HRT protocol is given on this page; the Reproductive Sage page covers gamete energetics in depth.

GH / IGF-1. Somatopause and metabolic GH resistance parallel other resistances — conservation or redirection when surplus for anabolism is missing. Exercise and fasting pulses GH adaptively when mitochondria can answer with biogenesis.

Gut peptides (GLP-1, GIP, CCK, PYY, ghrelin, etc.). They sense nutrient flux. Ultra-processed environments, gut-barrier stress, and endotoxemia (energy-dependent tight junctions) distort secretion and sensitivity. GLP-1 receptor agonists show broad benefits partly by bypassing defective endogenous signaling and imposing metabolic effects — yet root restoration of enteroendocrine function and downstream mito capacity offers more fundamental resolution. Agonists are bridges and tools, not proof that the fire was the alarm panel. No GLP-1 dosing or “how to stop / start” guidance; Diabetes / Obesity own clinical adjacency.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised November 4, 2026.

References

Cell signaling dysfunction

  1. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science. 2003;300:1140–2. doi:10.1126/science.1082889. PMID 12750520.
  2. Anderson EJ, Lustig ME, Boyle KE, et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest. 2009;119:573–81. doi:10.1172/JCI37048. PMID 19188683.
  3. Hoehn KL, Salmon AB, Hohnen-Behrens C, et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci U S A. 2009;106:17787–92. doi:10.1073/pnas.0902380106. PMID 19805130.
  4. Holloszy JO. "Deficiency" of mitochondria in muscle does not cause insulin resistance. Diabetes. 2013;62:1036–40. doi:10.2337/db12-1107. PMID 23520283.
  5. Lim EL, Hollingsworth KG, Aribisala BS, et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54:2506–14. doi:10.1007/s00125-011-2204-7. PMID 21656330.
  6. Myers MG Jr, Leibel RL, Seeley RJ, et al. Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab. 2010;21:643–51. doi:10.1016/j.tem.2010.08.002. PMID 20846876.
  7. Fliers E, Boelen A. An update on non-thyroidal illness syndrome. J Endocrinol Invest. 2021;44:1597–1607. doi:10.1007/s40618-020-01482-4. PMID 33320308.
  8. Miller WL. Steroid hormone synthesis in mitochondria. Mol Cell Endocrinol. 2013;379:62–73. doi:10.1016/j.mce.2013.04.014. PMID 23628605.
  9. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33:981–1030. doi:10.1210/er.2011-1034. PMID 23065822.
  10. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311–22. doi:10.1056/NEJMoa1603827. PMID 27295427.

See the notice at the top of this page. Working hypothesis, not medical advice.